dc.contributor.author |
Innajak S. |
|
dc.contributor.author |
Mahabusrakum W. |
|
dc.contributor.author |
Watanapokasin R. |
|
dc.date.accessioned |
2021-04-05T03:23:55Z |
|
dc.date.available |
2021-04-05T03:23:55Z |
|
dc.date.issued |
2016 |
|
dc.identifier.issn |
1021335X |
|
dc.identifier.other |
2-s2.0-84964053957 |
|
dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/13431 |
|
dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964053957&doi=10.3892%2for.2016.4655&partnerID=40&md5=9180c588d031d9758a1d63523e5776e4 |
|
dc.description.abstract |
Goniothalamin, a plant bioactive styrly-lactone, possesses many biological activities. In the present study, the anticancer effect of goniothalamin on human breast cancer cell line SK-BR-3 was investigated. The results showed that goniothalamin induced nuclear condensation, DNA fragmentation, apoptotic bodies and mitochondrial dysfunction as determined by JC-1 staining. Goniothalamin also increased the Bax/Bcl-2 ratio and expression of cleaved caspase-7, cleaved caspase-9 and cleaved PARP, but decreased Bcl-2 expression. In addition, goniothalamin induced apoptosis via p-JNK1/2 and p-p38 upregulation and inhibited cell survival via p-ERK1/2 and p-Akt downregulation. Notably, goniothalamin induced autophagy through upregulation of Atg7, Atg12-Atg5 conjugation and LC3II. The increased p-p38 and p-JNK1/2 and decreased p-Akt may lead to autophagy induction. Therefore, goniothalamin promoted apoptosis associated with autophagy induction in SK-BR-3 cells through p-p38 and p-JNK1/2 upregulation and p-Akt downregulation. The present study indicated that goniothalamin may be further used as a potential therapeutic candidate or may offer an alternative treatment for breast cancer. |
|
dc.subject |
antineoplastic agent |
|
dc.subject |
caspase 7 |
|
dc.subject |
caspase 9 |
|
dc.subject |
goniothalamin |
|
dc.subject |
mitogen activated protein kinase |
|
dc.subject |
mitogen activated protein kinase 1 |
|
dc.subject |
mitogen activated protein kinase 3 |
|
dc.subject |
mitogen activated protein kinase p38 |
|
dc.subject |
nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase |
|
dc.subject |
plant medicinal product |
|
dc.subject |
protein Bax |
|
dc.subject |
protein bcl 2 |
|
dc.subject |
protein kinase B |
|
dc.subject |
stress activated protein kinase 1 |
|
dc.subject |
unclassified drug |
|
dc.subject |
antineoplastic agent |
|
dc.subject |
goniothalamin |
|
dc.subject |
protein kinase B |
|
dc.subject |
pyrone derivative |
|
dc.subject |
antineoplastic activity |
|
dc.subject |
antiproliferative activity |
|
dc.subject |
apoptosis |
|
dc.subject |
Article |
|
dc.subject |
autophagy |
|
dc.subject |
cell survival |
|
dc.subject |
controlled study |
|
dc.subject |
DNA fragmentation |
|
dc.subject |
down regulation |
|
dc.subject |
human |
|
dc.subject |
human cell |
|
dc.subject |
IC50 |
|
dc.subject |
priority journal |
|
dc.subject |
protein cleavage |
|
dc.subject |
protein expression |
|
dc.subject |
signal transduction |
|
dc.subject |
upregulation |
|
dc.subject |
apoptosis |
|
dc.subject |
autophagy |
|
dc.subject |
Breast Neoplasms |
|
dc.subject |
cell proliferation |
|
dc.subject |
drug effects |
|
dc.subject |
drug screening |
|
dc.subject |
female |
|
dc.subject |
metabolism |
|
dc.subject |
mitochondrial membrane potential |
|
dc.subject |
tumor cell line |
|
dc.subject |
Antineoplastic Agents |
|
dc.subject |
Apoptosis |
|
dc.subject |
Autophagy |
|
dc.subject |
Breast Neoplasms |
|
dc.subject |
Cell Line, Tumor |
|
dc.subject |
Cell Proliferation |
|
dc.subject |
Drug Screening Assays, Antitumor |
|
dc.subject |
Female |
|
dc.subject |
Humans |
|
dc.subject |
MAP Kinase Signaling System |
|
dc.subject |
Membrane Potential, Mitochondrial |
|
dc.subject |
Proto-Oncogene Proteins c-akt |
|
dc.subject |
Pyrones |
|
dc.title |
Goniothalamin induces apoptosis associated with autophagy activation through MAPK signaling in SK-BR-3 cells |
|
dc.type |
Article |
|
dc.rights.holder |
Scopus |
|
dc.identifier.bibliograpycitation |
Oncology Reports. Vol 35, No.5 (2016), p.2851-2858 |
|
dc.identifier.doi |
10.3892/or.2016.4655 |
|